EGFR and lung cancer: Nakao et al. conducted a single-arm, phase 2 study (SPIRAL study) of osimertinib in 36 older patients with nonsmall cell lung cancer positive for the EGFR T790M acquisition resistance mutation as a second or subsequent line of therapy (5).